IN2014CN03333A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03333A
IN2014CN03333A IN3333CHN2014A IN2014CN03333A IN 2014CN03333 A IN2014CN03333 A IN 2014CN03333A IN 3333CHN2014 A IN3333CHN2014 A IN 3333CHN2014A IN 2014CN03333 A IN2014CN03333 A IN 2014CN03333A
Authority
IN
India
Prior art keywords
shk
potassium channel
inhibiting agent
modified
obesity
Prior art date
Application number
Other languages
English (en)
Inventor
George K Chandy
Sanjeev Kumar Upadhayay
Ping H Wang
Paolo Sassone Corsi
Kristin Lynn Eckel Mahan
Shawn Iadonato
Joseph Mukergee
Reza M Mirbolooki
Original Assignee
Univ California
Kineta One Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Kineta One Llc filed Critical Univ California
Publication of IN2014CN03333A publication Critical patent/IN2014CN03333A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN3333CHN2014 2011-10-03 2012-10-02 IN2014CN03333A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542751P 2011-10-03 2011-10-03
PCT/US2012/058495 WO2013052507A1 (en) 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Publications (1)

Publication Number Publication Date
IN2014CN03333A true IN2014CN03333A (pt) 2015-07-03

Family

ID=48044112

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3333CHN2014 IN2014CN03333A (pt) 2011-10-03 2012-10-02

Country Status (16)

Country Link
US (2) US20150072940A1 (pt)
EP (1) EP2763702A4 (pt)
JP (1) JP2014531469A (pt)
KR (1) KR20140108518A (pt)
CN (1) CN103987408A (pt)
AU (1) AU2012318736A1 (pt)
BR (1) BR112014008065A2 (pt)
CA (1) CA2850357A1 (pt)
HK (1) HK1201048A1 (pt)
IL (1) IL231873A0 (pt)
IN (1) IN2014CN03333A (pt)
MX (1) MX2014004029A (pt)
RU (1) RU2014117558A (pt)
SG (1) SG11201401193XA (pt)
TW (1) TW201321403A (pt)
WO (1) WO2013052507A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5118969B2 (ja) * 2004-10-07 2013-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア Ｋｖ１．３カリウムチャネルの選択的阻害におけるＳｈＫトキシンの類似体ならびにその使用方法
EP2717899A4 (en) * 2011-06-06 2015-07-29 Kineta One Llc PHARMACEUTICAL COMPOSITIONS BASED ON SHK AND METHODS OF MAKING AND USING THE SAME
IN2014CN03333A (pt) 2011-10-03 2015-07-03 Univ California
JP7211704B2 (ja) * 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
TWI698438B (zh) 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用
TWI701249B (zh) 2015-03-13 2020-08-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453270A (en) 1992-03-30 1995-09-26 Hypermetabolic Therapies, Inc. Pharmaceutical composition and method for hypermetabolic weight loss
WO1998023639A2 (en) 1996-11-27 1998-06-04 University Of Florida ShK TOXIN COMPOSITIONS AND METHODS OF USE
AU8052798A (en) * 1997-09-17 1999-04-05 Bachem Bioscience, Inc. Polypeptide compositions that inhibit potassium channel activity and uses herefor
JP3207823B2 (ja) 1999-04-28 2001-09-10 リノール油脂株式会社 共役リノール酸を有効成分とする褐色脂肪増加剤
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US6861405B2 (en) * 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
JP5118969B2 (ja) * 2004-10-07 2013-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア Ｋｖ１．３カリウムチャネルの選択的阻害におけるＳｈＫトキシンの類似体ならびにその使用方法
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
EP1928463A2 (en) * 2005-08-17 2008-06-11 Solvay Pharmaceuticals GmbH Method of using potassium channel inhibiting compounds
TW201026708A (en) * 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
IN2014CN03333A (pt) 2011-10-03 2015-07-03 Univ California

Also Published As

Publication number Publication date
US20170095530A1 (en) 2017-04-06
CN103987408A (zh) 2014-08-13
WO2013052507A1 (en) 2013-04-11
MX2014004029A (es) 2014-08-01
IL231873A0 (en) 2014-05-28
EP2763702A1 (en) 2014-08-13
TW201321403A (zh) 2013-06-01
HK1201048A1 (en) 2015-08-21
AU2012318736A1 (en) 2014-05-22
US9878006B2 (en) 2018-01-30
BR112014008065A2 (pt) 2019-09-24
CA2850357A1 (en) 2013-04-11
SG11201401193XA (en) 2014-05-29
JP2014531469A (ja) 2014-11-27
KR20140108518A (ko) 2014-09-11
RU2014117558A (ru) 2015-11-10
EP2763702A4 (en) 2015-04-15
US20150072940A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
MY160894A (en) Oligosaccharide composition for treating skin diseases
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
IN2014CN03333A (pt)
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
NZ626954A (en) Combination therapy of antibodies against human csf-1r and uses thereof
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
MX2013007189A (es) Metodos y composiciones adecuados para manejar glucosa en sangre en animales.
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
BR112013000433A2 (pt) diagnóstico e tratamento de câncer de mama
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
MX364220B (es) Metodos de tratamientos de fibrosis.
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
MX2014001271A (es) Tratamiento de diabetes de tipo 2 con fty720.
UA61499U (en) massage mat
UA63764U (ru) Применение экстракта из листьев сныти обыкновенной в качестве лечебно-профилактического средства с гепатопротекторным действием